Prognostic factors for thyroid cancer based on glucose metabolism
Project/Area Number |
16K11231
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Otorhinolaryngology
|
Research Institution | Osaka City General Hospital (2017-2019) Osaka University (2016) |
Principal Investigator |
Hanamoto Atsushi 地方独立行政法人大阪市民病院機構大阪市立総合医療センター(臨床研究センター), 臨床研究センター, 医長 (20625917)
|
Project Period (FY) |
2016-10-21 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 甲状腺癌 / FDG-PET / ワールブルグ効果 |
Outline of Final Research Achievements |
We investigated glucose metabolism as a prognostic factor for thyroid cancer. First, we examined FDG-PET, which is currently covered by insurance as a glucose metabolism test. These results showed that preoperative FDG-PET with large SUVmax, which indicates the degree of accumulation, and large tumor metabolic volume had a poor prognosis. As a further study, immunostaining of the excised specimen was performed. Glucose Transporter 1, Lactate Dehydrogenase A, Monocarboxylate Transporter 4, Fatty acid synthetase and Ki-67 were examined, but no significant difference in the degree of staining was observed in the degree of accumulation.
|
Academic Significance and Societal Importance of the Research Achievements |
甲状腺癌はハイリスク群とローリスク群に分けられ、ローリスク群は甲状腺葉切除+D1郭清、ハイリスク群は甲状腺全摘+頸部郭清+ヨード治療が推奨されている。しかし、両群ともに該当しない症例も多くあり、治療指針に関しては各施設にゆだねられている。この両群ともに該当しない症例をさらに細分化して、より正確な個別化治療ができることが望まれる。今回の研究でのFDGの集積の程度で更なる治療法の細分化ができる可能性がある。
|
Report
(5 results)
Research Products
(15 results)
-
[Journal Article] Paraneoplastic Cerebellar Degeneration and Lambert-Eaton Myasthenic Syndrome Associated with Neuroendocrine Carcinoma of the Oropharynx.2018
Author(s)
Takasugi J, Shimamura M, Koda T, Kishikawa T, Hanamoto A, Inohara H, Sato K, Morii E, Motomura M, Sakaguchi M, Nakatsuji Y, Mochizuki H.
-
Journal Title
Intern Med.
Volume: 57
Pages: 587-590
NAID
Related Report
Peer Reviewed
-
[Journal Article] Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach.2017
Author(s)
Miyabe J, Hanamoto A, Tatsumi M, Hamasaki T, Takenaka Y, Nakahara S, Kishikawa T, Suzuki M, Takemoto N, Michiba T, Yoshioka Y, Isohashi F, Konishi K, Ogawa K, Hatazawa J, Inohara H.
-
Journal Title
Cancer Sci.
Volume: 108
Issue: 10
Pages: 2030-2038
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan.2017
Author(s)
Takenaka Y, Takemoto N, Oya R, Ashida N, Kitamura T, Shimizu K, Takemura K, Michiba T, Hanamoto A, Suzuki M, Yamamoto Y, Uno A, Inohara H.
-
Journal Title
Sci Rep.
Volume: 7
Issue: 1
Pages: 7297-7297
DOI
Related Report
Peer Reviewed
-
[Journal Article] Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy.2017
Author(s)
Tanaka H, Takenaka Y, Nakahara S, Hanamoto A, Fukusumi T, Michiba T, Takemoto N, Cho H, Yamamoto M, Yamamoto Y, Inohara H.
-
Journal Title
Acta Otolaryngol.
Volume: 137
Issue: 6
Pages: 668-673
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer.2016
Author(s)
Takenaka Y, Takemoto N, Yasui T, Yamamoto Y, Uno A, Miyabe H, Ashida N, Shimizu K, Nakahara S, Hanamoto A, Fukusumi T, Michiba T, Cho H, Yamamoto M, Inohara H.
-
Journal Title
PLoS One.
Volume: -
Issue: 10
Pages: e0164057-e0164057
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.2016
Author(s)
Nakahara S, Hanamoto A, Seo Y, Miyaguchi S, Yamamoto Y, Tomiyama Y, Yoshii T, Takenaka Y, Yoshioka Y, Isohashi F, Ogawa K, Inohara H.
-
Journal Title
Jpn J Clin Oncol.
Volume: 46
Pages: 903-910
Related Report
Peer Reviewed
-
-
-
-
-
-